Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer

This study has been completed.
Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Cancer
2		Additional conditions recognized in this trial
			Ovarian Neoplasms
3		More general conditions related to this trial
			Adnexal Diseases
			Endocrine Gland Neoplasms
			Endocrine System Diseases
			Genital Diseases, Female
			Genital Neoplasms, Female
			Gonadal Disorders
			Neoplasms
			Neoplasms by Site
			Ovarian Diseases
			Urogenital Neoplasms
4		Interventions listed in this trial
			recombinant interleukin-12
5		Additional drug interventions recognized in this trial
			Interleukin-12
6		More general drug interventions related to this trial
			Adjuvants, Immunologic
			Angiogenesis Inhibitors
			Angiogenesis Modulating Agents
			Antineoplastic Agents
			Growth Inhibitors
			Growth Substances
			Immunologic Factors
			Pharmacologic Actions
			Physiological Effects of Drugs
			Therapeutic Uses
7		Sponsors listed in this trial
			UPMC Cancer Centers
			National Cancer Institute (NCI)